Document Detail

SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans.
MedLine Citation:
PMID:  15080855     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The administration of exogenous neurotensin can reduce the lower oesophageal sphincter pressure, but it is unclear whether this effect is pharmacological or physiological. AIM: A specific neurotensin receptor antagonist (SR 48692) was used to assess the effect of endogenous neurotensin on lower oesophageal sphincter function. METHODS: Twenty-four healthy male subjects were included in a double-blind, placebo-controlled, randomized, cross-over study designed to determine the effects of two single doses (90 and 300 mg, preceded by a loading dose) of SR 48692 on the resting lower oesophageal sphincter pressure, transient lower oesophageal sphincter relaxations, primary oesophageal peristalsis and oesophageal acid exposure. Oesophageal pH and motility recordings were performed during 1 h of fasting and 3 h post-prandially. Plasma neurotensin-like immunoreactivity release was determined by radioimmunoassay. RESULTS: During fasting, the lower oesophageal sphincter pressure, transient lower oesophageal sphincter relaxation rate and reflux episodes were similar with the two doses of SR 48692 and placebo. Meal ingestion induced a rise in plasma neurotensin-like immunoreactivity, a decrease in lower oesophageal sphincter pressure and an increase in both the transient lower oesophageal sphincter relaxation rate and the number of reflux episodes, which were not significantly modified by SR 48692. SR 48692 did not affect oesophageal primary peristalsis. CONCLUSION: This study shows that SR 48692, a specific neurotensin 1 receptor antagonist, has no effect on oesophageal motility in humans.
F Zerbib; T Piche; F Charles; J-P Galmiche; S Bruley des Varannes
Related Documents :
21274105 - Management of more severe cases of hypertension.
10573375 - Gastroesophageal reflux after combined lower esophageal sphincter and diaphragmatic cru...
9079605 - Nissen and toupet fundoplications effectively inhibit gastroesophageal reflux irrespect...
3820005 - Disorders of the esophageal motor activity in atresia of the esophagus.
3185305 - The influence of circulatory overload on extraalveolar microvessel endothelium of dog l...
1457755 - Hypertension and coronary artery disease in non-insulin dependent diabetes--cause and e...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  19     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-04-14     Completed Date:  2004-07-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  931-9     Citation Subset:  IM    
INSERM U539 and Centre d'Investigation Clinique INSERM, Department of Gastroenterology and Hepatology, University of Nantes, Nantes, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Esophagogastric Junction / drug effects
Esophagus / drug effects*
Gastrointestinal Motility / drug effects*
Hydrogen-Ion Concentration
Peristalsis / drug effects
Pyrazoles / pharmacokinetics,  pharmacology*
Quinolines / pharmacokinetics,  pharmacology*
Receptors, Neurotensin / antagonists & inhibitors*
Reg. No./Substance:
0/Pyrazoles; 0/Quinolines; 0/Receptors, Neurotensin; 146362-70-1/SR 48692

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of three different tests for the detection of stool antigens to diagnose Helicobacter pyl...
Next Document:  Restless legs syndrome: an overview of the current understanding and management.